{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:53:33Z","timestamp":1791327213645,"version":"4.3.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009408","name":"Fondation Brain Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009408","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s11060-024-04923-9","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T04:44:57Z","timestamp":1736138697000},"page":"317-326","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Advances in molecular prognostication and treatments in ependymoma"],"prefix":"10.1007","volume":"172","author":[{"given":"Emma","family":"Bakes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noralyn","family":"Ma\u00f1ucat-Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Ramaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan R.","family":"Hansford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"4923_CR1","volume-title":"Pizzo and poplack\u2019s pediatric oncology","author":"SMHL Blaney","year":"2021","unstructured":"Blaney SMHL, Adamson PC (2021) Pizzo and poplack\u2019s pediatric oncology. Williams and Wilkins, Lippincott"},{"issue":"5","key":"4923_CR2","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ccell.2015.04.002","volume":"27","author":"KW Pajtler","year":"2015","unstructured":"Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F et al (2015) Molecular classification of ependymal tumors across All CNS compartments, histopathological grades, and age groups. Cancer Cell 27(5):728\u2013743","journal-title":"Cancer Cell"},{"issue":"3","key":"4923_CR3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00401-020-02260-5","volume":"141","author":"V Zschernack","year":"2021","unstructured":"Zschernack V, Junger ST, Mynarek M, Rutkowski S, Garre ML, Ebinger M et al (2021) Supratentorial ependymoma in childhood: more than just RELA or YAP. Acta Neuropathol 141(3):455\u2013466","journal-title":"Acta Neuropathol"},{"issue":"8","key":"4923_CR4","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231\u20131251","journal-title":"Neuro Oncol"},{"issue":"6","key":"4923_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803\u2013820","journal-title":"Acta Neuropathol"},{"issue":"21","key":"4923_CR6","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1200\/JCO.2017.73.1265","volume":"35","author":"TE Merchant","year":"2017","unstructured":"Merchant TE (2017) Current clinical challenges in childhood ependymoma: a focused review. J Clin Oncol 35(21):2364\u20132369","journal-title":"J Clin Oncol"},{"key":"4923_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1477-5751-10-7","volume":"10","author":"DW Ellison","year":"2011","unstructured":"Ellison DW, Kocak M, Figarella-Branger D, Felice G, Catherine G, Pietsch T et al (2011) Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed 10:7","journal-title":"J Negat Results Biomed"},{"issue":"4","key":"4923_CR8","doi-asserted-by":"publisher","first-page":"e13068","DOI":"10.1111\/bpa.13068","volume":"32","author":"C Kresbach","year":"2022","unstructured":"Kresbach C, Neyazi S, Schuller U (2022) Updates in the classification of ependymal neoplasms: the 2021 WHO Classification and beyond. Brain Pathol 32(4):e13068","journal-title":"Brain Pathol"},{"issue":"5","key":"4923_CR9","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/bpa.12866","volume":"30","author":"DW Ellison","year":"2020","unstructured":"Ellison DW, Aldape KD, Capper D, Fouladi M, Gilbert MR, Gilbertson RJ et al (2020) cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathol 30(5):863\u2013866","journal-title":"Brain Pathol"},{"issue":"7697","key":"4923_CR10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature26000","volume":"555","author":"D Capper","year":"2018","unstructured":"Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D et al (2018) DNA methylation-based classification of central nervous system tumours. Nature 555(7697):469\u2013474","journal-title":"Nature"},{"issue":"5","key":"4923_CR11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00401-017-1752-4","volume":"134","author":"P Panwalkar","year":"2017","unstructured":"Panwalkar P, Clark J, Ramaswamy V, Hawes D, Yang F, Dunham C et al (2017) Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group\u2014a childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol 134(5):705\u2013714","journal-title":"Acta Neuropathol"},{"issue":"3","key":"4923_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s003810050487","volume":"16","author":"L Palma","year":"2000","unstructured":"Palma L, Celli P, Mariottini A, Zalaffi A, Schettini G (2000) The importance of surgery in supratentorial ependymomas: long-term survival in a series of 23 cases. Childs Nerv Syst 16(3):170\u2013175","journal-title":"Childs Nerv Syst"},{"issue":"1","key":"4923_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000028683","volume":"29","author":"J Hukin","year":"1998","unstructured":"Hukin J, Epstein F, Lefton D, Allen J (1998) Treatment of intracranial ependymoma by surgery alone. Pediatr Neurosurg 29(1):40\u201345","journal-title":"Pediatr Neurosurg"},{"issue":"3","key":"4923_CR14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S1470-2045(08)70342-5","volume":"10","author":"TE Merchant","year":"2009","unstructured":"Merchant TE, Li C, Xiong X, Kun LE, Boop FA, Sanford RA (2009) Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol 10(3):258\u2013266","journal-title":"Lancet Oncol"},{"issue":"12","key":"4923_CR15","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1200\/JCO.18.01765","volume":"37","author":"TE Merchant","year":"2019","unstructured":"Merchant TE, Bendel AE, Sabin ND, Burger PC, Shaw DW, Chang E et al (2019) Conformal radiation therapy for pediatric ependymoma, chemotherapy for incompletely resected ependymoma, and observation for completely resected. Supratentorial Ependymoma J Clin Oncol 37(12):974\u2013983","journal-title":"Supratentorial Ependymoma J Clin Oncol"},{"issue":"7489","key":"4923_CR16","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nature13109","volume":"506","author":"M Parker","year":"2014","unstructured":"Parker M, Mohankumar KM, Punchihewa C, Weinlich R, Dalton JD, Li Y et al (2014) C11orf95-RELA fusions drive oncogenic NF-kappaB signalling in ependymoma. Nature 506(7489):451\u2013455","journal-title":"Nature"},{"issue":"33","key":"4923_CR17","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.1200\/JCO.2006.06.3701","volume":"24","author":"P Modena","year":"2006","unstructured":"Modena P, Lualdi E, Facchinetti F, Veltman J, Reid JF, Minardi S et al (2006) Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol 24(33):5223\u20135233","journal-title":"J Clin Oncol"},{"issue":"2","key":"4923_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ccr.2011.07.007","volume":"20","author":"H Witt","year":"2011","unstructured":"Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R et al (2011) Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20(2):143\u2013157","journal-title":"Cancer Cell"},{"issue":"4","key":"4923_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ccr.2005.09.001","volume":"8","author":"MD Taylor","year":"2005","unstructured":"Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, Jensen P et al (2005) Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 8(4):323\u2013335","journal-title":"Cancer Cell"},{"issue":"11","key":"4923_CR20","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2007.15.4195","volume":"27","author":"S Puget","year":"2009","unstructured":"Puget S, Grill J, Valent A, Bieche I, Dantas-Barbosa C, Kauffmann A et al (2009) Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas. J Clin Oncol 27(11):1884\u20131892","journal-title":"J Clin Oncol"},{"issue":"7306","key":"4923_CR21","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/nature09173","volume":"466","author":"RA Johnson","year":"2010","unstructured":"Johnson RA, Wright KD, Poppleton H, Mohankumar KM, Finkelstein D, Pounds SB et al (2010) Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 466(7306):632\u2013636","journal-title":"Nature"},{"issue":"7489","key":"4923_CR22","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature13108","volume":"506","author":"SC Mack","year":"2014","unstructured":"Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stutz AM et al (2014) Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506(7489):445\u2013450","journal-title":"Nature"},{"issue":"7","key":"4923_CR23","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/jnen\/nlad038","volume":"82","author":"MA Gubbiotti","year":"2023","unstructured":"Gubbiotti MA, Madsen PJ, Tucker AM, Abdullaev Z, Aldape K, Shekdar K et al (2023) ZFTA-fused supratentorial ependymoma with a novel fusion partner, DUX4. J Neuropathol Exp Neurol 82(7):668\u2013671","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"4923_CR24","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00401-014-1264-4","volume":"127","author":"T Pietsch","year":"2014","unstructured":"Pietsch T, Wohlers I, Goschzik T, Dreschmann V, Denkhaus D, Dorner E et al (2014) Supratentorial ependymomas of childhood carry C11orf95-RELA fusions leading to pathological activation of the NF-kappaB signaling pathway. Acta Neuropathol 127(4):609\u2013611","journal-title":"Acta Neuropathol"},{"issue":"9","key":"4923_CR25","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1158\/2159-8290.CD-20-0963","volume":"11","author":"T Zheng","year":"2021","unstructured":"Zheng T, Ghasemi DR, Okonechnikov K, Korshunov A, Sill M, Maass KK et al (2021) Cross-species genomics reveals oncogenic dependencies in ZFTA\/C11orf95 fusion-positive supratentorial ependymomas. Cancer Discov 11(9):2230\u20132247","journal-title":"Cancer Discov"},{"issue":"9","key":"4923_CR26","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1158\/2159-8290.CD-20-1052","volume":"11","author":"R Kupp","year":"2021","unstructured":"Kupp R, Ruff L, Terranova S, Nathan E, Ballereau S, Stark R et al (2021) ZFTA translocations constitute ependymoma chromatin remodeling and transcription factors. Cancer Discov 11(9):2216\u20132229","journal-title":"Cancer Discov"},{"issue":"9","key":"4923_CR27","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1158\/2159-8290.CD-20-1066","volume":"11","author":"A Arabzade","year":"2021","unstructured":"Arabzade A, Zhao Y, Varadharajan S, Chen HC, Jessa S, Rivas B et al (2021) ZFTA-RELA dictates oncogenic transcriptional programs to drive aggressive supratentorial ependymoma. Cancer Discov 11(9):2200\u20132215","journal-title":"Cancer Discov"},{"issue":"1","key":"4923_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40478-023-01695-7","volume":"12","author":"A Tauziede-Espariat","year":"2024","unstructured":"Tauziede-Espariat A, Nicaise Y, Sievers P, Sahm F, von Deimling A, Guillemot D et al (2024) CNS tumors with PLAGL1-fusion: beyond ZFTA and YAP1 in the genetic spectrum of supratentorial ependymomas. Acta Neuropathol Commun 12(1):55","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"4923_CR29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s40478-021-01238-y","volume":"9","author":"A Tauziede-Espariat","year":"2021","unstructured":"Tauziede-Espariat A, Siegfried A, Nicaise Y, Kergrohen T, Sievers P, Vasiljevic A et al (2021) Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1\/2 fusions. Acta Neuropathol Commun 9(1):135","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"4923_CR30","first-page":"vdad057","volume":"5","author":"CH Ng","year":"2023","unstructured":"Ng CH, Obrecht D, Wells O, Zapotocky M, Sumerauer D, Coltin H et al (2023) A multi-institutional retrospective pooled outcome analysis of molecularly annotated pediatric supratentorial ZFTA-fused ependymoma. Neurooncol Adv. 5(1):vdad057","journal-title":"Neurooncol Adv."},{"issue":"1","key":"4923_CR31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40478-018-0630-1","volume":"6","author":"K Fukuoka","year":"2018","unstructured":"Fukuoka K, Kanemura Y, Shofuda T, Fukushima S, Yamashita S, Narushima D et al (2018) Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors. Acta Neuropathol Commun 6(1):134","journal-title":"Acta Neuropathol Commun"},{"issue":"10","key":"4923_CR32","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1093\/neuonc\/noz069","volume":"21","author":"SA Upadhyaya","year":"2019","unstructured":"Upadhyaya SA, Robinson GW, Onar-Thomas A, Orr BA, Billups CA, Bowers DC et al (2019) Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial. Neuro Oncol 21(10):1319\u20131330","journal-title":"Neuro Oncol"},{"key":"4923_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae064.231","author":"AA Smith","year":"2024","unstructured":"Smith AA, Lensing S, Onar-Thomas A, Leary S, Fouladi M, Foreman NK, Ellison DW (2024) EPEN-29: is the outcome of supratentorial ependymoma with ZFTA fusion really poor? Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noae064.231","journal-title":"Neuro Oncol"},{"issue":"3","key":"4923_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00401-020-02169-z","volume":"140","author":"ST Junger","year":"2020","unstructured":"Junger ST, Andreiuolo F, Mynarek M, Wohlers I, Rahmann S, Klein-Hitpass L et al (2020) CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort. Acta Neuropathol 140(3):405\u2013407","journal-title":"Acta Neuropathol"},{"issue":"2","key":"4923_CR35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/bpa.12659","volume":"29","author":"F Andreiuolo","year":"2019","unstructured":"Andreiuolo F, Varlet P, Tauziede-Espariat A, Junger ST, Dorner E, Dreschmann V et al (2019) Childhood supratentorial ependymomas with YAP1-MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features. Brain Pathol 29(2):205\u2013216","journal-title":"Brain Pathol"},{"issue":"1","key":"4923_CR36","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1038\/s41467-019-11884-5","volume":"10","author":"KW Pajtler","year":"2019","unstructured":"Pajtler KW, Wei Y, Okonechnikov K, Silva PBG, Vouri M, Zhang L et al (2019) YAP1 subgroup supratentorial ependymoma requires TEAD and nuclear factor I-mediated transcriptional programmes for tumorigenesis. Nat Commun 10(1):3914","journal-title":"Nat Commun"},{"issue":"1","key":"4923_CR37","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s40478-022-01442-4","volume":"10","author":"C Mariet","year":"2022","unstructured":"Mariet C, Castel D, Grill J, Saffroy R, Dangouloff-Ros V, Boddaert N et al (2022) Posterior fossa ependymoma H3 K27-mutant: an integrated radiological and histomolecular tumor analysis. Acta Neuropathol Commun 10(1):137","journal-title":"Acta Neuropathol Commun"},{"key":"4923_CR38","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000537694","volume":"46","author":"AS Kardian","year":"2024","unstructured":"Kardian AS, Mack S (2024) The intersection of epigenetic alterations and developmental state in pediatric ependymomas. Dev Neurosci 46:365\u2013372","journal-title":"Dev Neurosci"},{"issue":"2","key":"4923_CR39","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00401-018-1877-0","volume":"136","author":"KW Pajtler","year":"2018","unstructured":"Pajtler KW, Wen J, Sill M, Lin T, Orisme W, Tang B et al (2018) Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathol 136(2):211\u2013226","journal-title":"Acta Neuropathol"},{"issue":"1","key":"4923_CR40","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1038\/s41467-019-09981-6","volume":"10","author":"SU Jain","year":"2019","unstructured":"Jain SU, Do TJ, Lund PJ, Rashoff AQ, Diehl KL, Cieslik M et al (2019) PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism. Nat Commun 10(1):2146","journal-title":"Nat Commun"},{"issue":"18","key":"4923_CR41","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1016\/j.cell.2024.06.023","volume":"187","author":"MJ Johnston","year":"2024","unstructured":"Johnston MJ, Lee JJY, Hu B, Nikolic A, Hasheminasabgorji E, Baguette A et al (2024) TULIPs decorate the three-dimensional genome of PFA ependymoma. Cell 187(18):4926-4945.e22","journal-title":"Cell"},{"issue":"614","key":"4923_CR42","doi-asserted-by":"publisher","first-page":"eabc0497","DOI":"10.1126\/scitranslmed.abc0497","volume":"13","author":"P Panwalkar","year":"2021","unstructured":"Panwalkar P, Tamrazi B, Dang D, Chung C, Sweha S, Natarajan SK et al (2021) Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas. Sci Transl Med. 13(614):eabc0497","journal-title":"Sci Transl Med."},{"issue":"10","key":"4923_CR43","doi-asserted-by":"publisher","first-page":"827","DOI":"10.18632\/oncoscience.202","volume":"2","author":"KW Pajtler","year":"2015","unstructured":"Pajtler KW, Pfister SM, Kool M (2015) Molecular dissection of ependymomas. Oncoscience 2(10):827\u2013828","journal-title":"Oncoscience"},{"issue":"8","key":"4923_CR44","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1093\/neuonc\/noab034","volume":"23","author":"LV Baroni","year":"2021","unstructured":"Baroni LV, Sundaresan L, Heled A, Coltin H, Pajtler KW, Lin T et al (2021) Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro Oncol 23(8):1360\u20131370","journal-title":"Neuro Oncol"},{"key":"4923_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad096","author":"AM Donson","year":"2023","unstructured":"Donson AM, Bertrand KC, Riemondy KA, Gao D, Zhuang Y, Sanford B et al (2023) Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: a multicenter study. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noad096","journal-title":"Neuro Oncol"},{"issue":"11","key":"4923_CR46","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1002\/cncr.31995","volume":"125","author":"M Zapotocky","year":"2019","unstructured":"Zapotocky M, Beera K, Adamski J, Laperierre N, Guger S, Janzen L et al (2019) Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: cure at a cost. Cancer 125(11):1867\u20131876","journal-title":"Cancer"},{"issue":"2","key":"4923_CR47","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00401-018-1888-x","volume":"136","author":"FMG Cavalli","year":"2018","unstructured":"Cavalli FMG, Hubner JM, Sharma T, Luu B, Sill M, Zapotocky M et al (2018) Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathol 136(2):227\u2013237","journal-title":"Acta Neuropathol"},{"issue":"21","key":"4923_CR48","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1200\/JCO.2015.65.7825","volume":"34","author":"V Ramaswamy","year":"2016","unstructured":"Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW et al (2016) Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: a retrospective multicohort analysis. J Clin Oncol 34(21):2468\u20132477","journal-title":"J Clin Oncol"},{"issue":"1","key":"4923_CR49","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00401-016-1643-0","volume":"133","author":"KW Pajtler","year":"2017","unstructured":"Pajtler KW, Mack SC, Ramaswamy V, Smith CA, Witt H, Smith A et al (2017) The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol 133(1):5\u201312","journal-title":"Acta Neuropathol"},{"issue":"9","key":"4923_CR50","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/jnen\/nlz064","volume":"78","author":"AA Swanson","year":"2019","unstructured":"Swanson AA, Raghunathan A, Jenkins RB, Messing-Junger M, Pietsch T, Clarke MJ et al (2019) Spinal cord ependymomas with mycn amplification show aggressive clinical behavior. J Neuropathol Exp Neurol 78(9):791\u2013797","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6","key":"4923_CR51","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00401-019-02056-2","volume":"138","author":"DR Ghasemi","year":"2019","unstructured":"Ghasemi DR, Sill M, Okonechnikov K, Korshunov A, Yip S, Schutz PW et al (2019) MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathol 138(6):1075\u20131089","journal-title":"Acta Neuropathol"},{"issue":"1","key":"4923_CR52","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s00401-023-02668-9","volume":"147","author":"S Neyazi","year":"2024","unstructured":"Neyazi S, Yamazawa E, Hack K, Tanaka S, Nagae G, Kresbach C et al (2024) Transcriptomic and epigenetic dissection of spinal ependymoma (SP-EPN) identifies clinically relevant subtypes enriched for tumors with and without NF2 mutation. Acta Neuropathol 147(1):22","journal-title":"Acta Neuropathol"},{"issue":"2","key":"4923_CR53","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ijrobp.2012.05.001","volume":"85","author":"HC Agbahiwe","year":"2013","unstructured":"Agbahiwe HC, Wharam M, Batra S, Cohen K, Terezakis SA (2013) Management of pediatric myxopapillary ependymoma: the role of adjuvant radiation. Int J Radiat Oncol Biol Phys 85(2):421\u2013427","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4923_CR54","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1016\/j.wneu.2019.12.128","volume":"136","author":"A Abdallah","year":"2020","unstructured":"Abdallah A, Emel E, Gunduz HB, Sofuoglu OE, Asilturk M, Abdallah BG (2020) Long-term surgical resection outcomes of pediatric myxopapillary ependymoma: experience of two centers and brief literature review. World Neurosurg 136:e245\u2013e261","journal-title":"World Neurosurg"},{"issue":"8","key":"4923_CR55","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/jjco\/hyad056","volume":"53","author":"J Yamaguchi","year":"2023","unstructured":"Yamaguchi J, Ohka F, Motomura K, Saito R (2023) Latest classification of ependymoma in the molecular era and advances in its treatment: a review. Jpn J Clin Oncol 53(8):653\u2013663","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"4923_CR56","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40478-020-00973-y","volume":"8","author":"M Raffeld","year":"2020","unstructured":"Raffeld M, Abdullaev Z, Pack SD, Xi L, Nagaraj S, Briceno N et al (2020) High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma. Acta Neuropathol Commun 8(1):101","journal-title":"Acta Neuropathol Commun"},{"issue":"36","key":"4923_CR57","doi-asserted-by":"publisher","first-page":"57525","DOI":"10.18632\/oncotarget.10544","volume":"7","author":"L Vaughan","year":"2016","unstructured":"Vaughan L, Clarke PA, Barker K, Chanthery Y, Gustafson CW, Tucker E et al (2016) Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. Oncotarget 7(36):57525\u201357544","journal-title":"Oncotarget"},{"issue":"6","key":"4923_CR58","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/neuonc\/noac012","volume":"24","author":"TA Ritzmann","year":"2022","unstructured":"Ritzmann TA, Chapman RJ, Kilday JP, Thorp N, Modena P, Dineen RA et al (2022) SIOP ependymoma I: final results, long-term follow-up, and molecular analysis of the trial cohort\u2014A BIOMECA Consortium Study. Neuro Oncol 24(6):936\u2013948","journal-title":"Neuro Oncol"},{"key":"4923_CR59","doi-asserted-by":"publisher","first-page":"887544","DOI":"10.3389\/fneur.2022.887544","volume":"13","author":"P Leblond","year":"2022","unstructured":"Leblond P, Massimino M, English M, Ritzmann TA, Gandola L, Calaminus G et al (2022) Toward improved diagnosis accuracy and treatment of children, adolescents, and young adults with ependymoma: the international siop ependymoma II protocol. Front Neurol 13:887544","journal-title":"Front Neurol"},{"issue":"1","key":"4923_CR60","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/pbc.20935","volume":"49","author":"S Zacharoulis","year":"2007","unstructured":"Zacharoulis S, Levy A, Chi SN, Gardner S, Rosenblum M, Miller DC et al (2007) Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer 49(1):34\u201340","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"4923_CR61","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/S1470-2045(07)70208-5","volume":"8","author":"RG Grundy","year":"2007","unstructured":"Grundy RG, Wilne SA, Weston CL, Robinson K, Lashford LS, Ironside J et al (2007) Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG\/SIOP prospective study. Lancet Oncol 8(8):696\u2013705","journal-title":"Lancet Oncol"},{"issue":"12","key":"4923_CR62","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1093\/neuonc\/nov181","volume":"17","author":"KD Wright","year":"2015","unstructured":"Wright KD, Daryani VM, Turner DC, Onar-Thomas A, Boulos N, Orr BA et al (2015) Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. Neuro Oncol 17(12):1620\u20131627","journal-title":"Neuro Oncol"},{"issue":"11","key":"4923_CR63","first-page":"e49086","volume":"15","author":"E Villanueva-Castro","year":"2023","unstructured":"Villanueva-Castro E, Meraz-Soto JM, Hernandez-Dehesa IA, Tena-Suck ML, Hernandez-Resendiz R, Mateo-Nouel EJ et al (2023) Spinal ependymomas: an updated WHO classification and a narrative review. Cureus 15(11):e49086","journal-title":"Cureus"},{"issue":"8","key":"4923_CR64","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s11912-022-01260-w","volume":"24","author":"R Ruda","year":"2022","unstructured":"Ruda R, Bruno F, Pellerino A, Soffietti R (2022) Ependymoma: evaluation and management updates. Curr Oncol Rep 24(8):985\u2013993","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"4923_CR65","doi-asserted-by":"publisher","first-page":"107585","DOI":"10.1016\/j.isci.2023.107585","volume":"26","author":"AM Griesinger","year":"2023","unstructured":"Griesinger AM, Riemondy K, Eswaran N, Donson AM, Willard N, Prince EW et al (2023) Multi-omic approach identifies hypoxic tumor-associated myeloid cells that drive immunobiology of high-risk pediatric ependymoma. iScience. 26(9):107585","journal-title":"iScience."}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04923-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-024-04923-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04923-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T14:28:01Z","timestamp":1743431281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-024-04923-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["4923"],"URL":"https:\/\/doi.org\/10.1007\/s11060-024-04923-9","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"14 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}